US product launch of LPLDL® at trade show

RNS Number : 8198O

OptiBiotix Health PLC

24 August 2017

 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

US product launch of LP_LDL® at Supply Side West trade show

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it plans for a US launch of LP_LDL®, its cholesterol and blood pressure lowering product, at Supply Side West in Las Vegas, on 27-28 September 2017. This follows the global manufacturing and supply agreement with Sacco S.r.l. ("Sacco") announced on 22 August 2017.

The Supply Side West tradeshow brings together more than 15,000 ingredient buyers and suppliers from the supplement, beverage, functional food, personal care and sports nutrition industries and is viewed as one of the world's leading trade fairs for the food and drinks industry.

OptiBiotix will co-exhibit with Sacco and will present new product concepts, as well as launching existing products containing its cholesterol reducing strain (LP_LDL®) at the show, including:-

·      CholBiome®: a proprietary formulation containing LP_LDL® to reduce cholesterol levels and blood pressure; and

·      CardioBiome®: a proprietary formulation containing LP_LDL® to reduce a wide range of cardiovascular disease factors and improve long term heart health.

The US launch of LP_LDL®, CholBiome® and CardioBiome® at Supply Side West is the first of a number of commercial steps taken to supply LP_LDL® to food, beverage, consumer healthcare and pharmaceutical partners to be incorporated into final formulations and presentations for distribution and sale into the US market.

The US is one of the largest and fastest-growing probiotic markets in the world, with supplements alone accounting for US$2.06bn sales, with a projected 55% growth to US$3.3bn by 2021.  Discussions continue to progress with corporate partners for the manufacture and distribution of products containing LP_LDL® in the European, Asian and other international markets.

Stephen O'Hara, CEO of OptiBiotix, commented: "OptiBiotix has made significant progress in raising industry awareness of its LP_LDL® strain. This has created a high level of interest in commercialising products containing LP_LDL® as a component in higher value branded products in markets globally. Exhibiting at Supply Side West creates the opportunity to communicate with high-end decision makers in the US market with the potential to generate revenues for different formulations and presentations across numerous applications at multiple points in the value chain with US and international partners."

OptiBiotix and Sacco will be available at booth Q137.

For further information, please contact:

OptiBiotix Health plc		www.optibiotix.com
Stephen O'Hara, Chief Executive		Contact via Walbrook below
Cairn Financial Advisers LLP (NOMAD)		Tel: [phone]
Liam Murray / Jo Turner
finnCap (Broker)		Tel: [phone]
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)
Tony Quirke / Abigail Wayne (Corporate Broking)
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Anna Dunphy		Mob: [phone]

About OptiBiotix - www.optibiotix.com 

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

END

 

 

PRLPGUMURUPMGAW